Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA)

By Jameson Michael B   Head Michelle  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 10, 2011-10 ,pp. : 1315-1326

Informa Healthcare

Access to resources Recommend Favorite

The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities

By Head Michelle   Jameson Michael B  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 295-304

Informa Healthcare

Access to resources Recommend Favorite

Enhancement of the action of the antivascular drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA; ASA404) by non-steroidal anti-inflammatory drugs

By Wang L.-C.   Ching Lai-Ming   Paxton James   Kestell Philip   Sutherland Rachel   Zhuang Li   Baguley Bruce  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 280-284

Springer Publishing Company

Access to resources Recommend Favorite

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

By McKeage Mark J  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 1, 2008-01 ,pp. : 23-29

Informa Healthcare

Access to resources Recommend Favorite

ASA404: update on drug development

By Rehman Farah   Rustin Gordon  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1547-1551

Informa Healthcare

Access to resources Recommend Favorite